256 related articles for article (PubMed ID: 28135008)
1. Interferon-Mediated Tumor Resistance to Oncolytic Virotherapy.
Ebrahimi S; Ghorbani E; Khazaei M; Avan A; Ryzhikov M; Azadmanesh K; Hassanian SM
J Cell Biochem; 2017 Aug; 118(8):1994-1999. PubMed ID: 28135008
[TBL] [Abstract][Full Text] [Related]
2. Niche Extracellular Matrix Components and Their Influence on HSC.
Domingues MJ; Cao H; Heazlewood SY; Cao B; Nilsson SK
J Cell Biochem; 2017 Aug; 118(8):1984-1993. PubMed ID: 28112429
[TBL] [Abstract][Full Text] [Related]
3. Oncolytic Immunotherapy for Treatment of Cancer.
Tsun A; Miao XN; Wang CM; Yu DC
Adv Exp Med Biol; 2016; 909():241-83. PubMed ID: 27240460
[TBL] [Abstract][Full Text] [Related]
4. Defects in interferon pathways as potential biomarkers of sensitivity to oncolytic viruses.
Matveeva OV; Chumakov PM
Rev Med Virol; 2018 Nov; 28(6):e2008. PubMed ID: 30209859
[TBL] [Abstract][Full Text] [Related]
5. CXCL12/CXCR4 blockade by oncolytic virotherapy inhibits ovarian cancer growth by decreasing immunosuppression and targeting cancer-initiating cells.
Gil M; Komorowski MP; Seshadri M; Rokita H; McGray AJ; Opyrchal M; Odunsi KO; Kozbor D
J Immunol; 2014 Nov; 193(10):5327-37. PubMed ID: 25320277
[TBL] [Abstract][Full Text] [Related]
6. Interferon Beta and Interferon Alpha 2a Differentially Protect Head and Neck Cancer Cells from Vesicular Stomatitis Virus-Induced Oncolysis.
Westcott MM; Liu J; Rajani K; D'Agostino R; Lyles DS; Porosnicu M
J Virol; 2015 Aug; 89(15):7944-54. PubMed ID: 25995245
[TBL] [Abstract][Full Text] [Related]
7. Germline mutations in the bone marrow microenvironment and dysregulated hematopoiesis.
Miller LH; Qu CK; Pauly M
Exp Hematol; 2018 Oct; 66():17-26. PubMed ID: 30076950
[TBL] [Abstract][Full Text] [Related]
8. Biochemical Changes in the Niche Following Tumor Cell Invasion.
Decker AM; Cackowski FC; Jung Y; Taichman RS
J Cell Biochem; 2017 Aug; 118(8):1956-1964. PubMed ID: 27982511
[TBL] [Abstract][Full Text] [Related]
9. Targeting CXCL12/CXCR4 signaling with oncolytic virotherapy disrupts tumor vasculature and inhibits breast cancer metastases.
Gil M; Seshadri M; Komorowski MP; Abrams SI; Kozbor D
Proc Natl Acad Sci U S A; 2013 Apr; 110(14):E1291-300. PubMed ID: 23509246
[TBL] [Abstract][Full Text] [Related]
10. The Efficacy of Oncolytic Adenovirus Is Mediated by T-cell Responses against Virus and Tumor in Syrian Hamster Model.
Li X; Wang P; Li H; Du X; Liu M; Huang Q; Wang Y; Wang S
Clin Cancer Res; 2017 Jan; 23(1):239-249. PubMed ID: 27435398
[TBL] [Abstract][Full Text] [Related]
11. Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade.
Marchini A; Scott EM; Rommelaere J
Viruses; 2016 Jan; 8(1):. PubMed ID: 26751469
[TBL] [Abstract][Full Text] [Related]
12. The gamble between oncolytic virus therapy and IFN.
Li Q; Tan F; Wang Y; Liu X; Kong X; Meng J; Yang L; Cen S
Front Immunol; 2022; 13():971674. PubMed ID: 36090998
[TBL] [Abstract][Full Text] [Related]
13. Improving antitumor efficacy via combinatorial regimens of oncolytic virotherapy.
Zhang B; Cheng P
Mol Cancer; 2020 Nov; 19(1):158. PubMed ID: 33172438
[TBL] [Abstract][Full Text] [Related]
14. Oncolytic Sindbis virus targets tumors defective in the interferon response and induces significant bystander antitumor immunity in vivo.
Huang PY; Guo JH; Hwang LH
Mol Ther; 2012 Feb; 20(2):298-305. PubMed ID: 22068428
[TBL] [Abstract][Full Text] [Related]
15. Multidirectional Strategies for Targeted Delivery of Oncolytic Viruses by Tumor Infiltrating Immune Cells.
Osali A; Zhiani M; Ghaebi M; Meymanat M; Esmaeilzadeh A
Pharmacol Res; 2020 Nov; 161():105094. PubMed ID: 32795509
[TBL] [Abstract][Full Text] [Related]
16. Targeting autophagy to enhance oncolytic virus-based cancer therapy.
Meng S; Xu J; Wu Y; Ding C
Expert Opin Biol Ther; 2013 Jun; 13(6):863-73. PubMed ID: 23488666
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic potency of oncolytic virotherapy-induced cancer stem cells targeting in brain tumors, current status, and perspectives.
Bahreyni A; Ghorbani E; Fuji H; Ryzhikov M; Khazaei M; Erfani M; Avan A; Hassanian SM; Azadmanesh K
J Cell Biochem; 2019 Mar; 120(3):2766-2773. PubMed ID: 30321455
[TBL] [Abstract][Full Text] [Related]
18. Concise Review: Targeting Cancer Stem Cells and Their Supporting Niche Using Oncolytic Viruses.
Crupi MJF; Bell JC; Singaravelu R
Stem Cells; 2019 Jun; 37(6):716-723. PubMed ID: 30875126
[TBL] [Abstract][Full Text] [Related]
19. Lighting a Fire in the Tumor Microenvironment Using Oncolytic Immunotherapy.
Achard C; Surendran A; Wedge ME; Ungerechts G; Bell J; Ilkow CS
EBioMedicine; 2018 May; 31():17-24. PubMed ID: 29724655
[TBL] [Abstract][Full Text] [Related]
20. Immune Conversion of Tumor Microenvironment by Oncolytic Viruses: The Protoparvovirus H-1PV Case Study.
Marchini A; Daeffler L; Pozdeev VI; Angelova A; Rommelaere J
Front Immunol; 2019; 10():1848. PubMed ID: 31440242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
